Clinical significance of the cytochrome P450 2C19 genetic polymorphism
- PMID:12222994
- DOI: 10.2165/00003088-200241120-00002
Clinical significance of the cytochrome P450 2C19 genetic polymorphism
Abstract
Cytochrome P450 2C19 (CYP2C19) is the main (or partial) cause for large differences in the pharmacokinetics of a number of clinically important drugs. On the basis of their ability to metabolise (S)-mephenytoin or other CYP2C19 substrates, individuals can be classified as extensive metabolisers (EMs) or poor metabolisers (PMs). Eight variant alleles (CYP2C19*2 to CYP2C19*8) that predict PMs have been identified. The distribution of EM and PM genotypes and phenotypes shows wide interethnic differences. Nongenetic factors such as enzyme inhibition and induction, old age and liver cirrhosis can also modulate CYP2C19 activity. In EMs, approximately 80% of doses of the proton pump inhibitors (PPIs) omeprazole, lansoprazole and pantoprazole seem to be cleared by CYP2C19, whereas CYP3A is more important in PMs. Five-fold higher exposure to these drugs is observed in PMs than in EMs of CYP2C19, and further increases occur during inhibition of CYP3A-catalysed alternative metabolic pathways in PMs. As a result, PMs of CYP2C19 experience more effective acid suppression and better healing of duodenal and gastric ulcers during treatment with omeprazole and lansoprazole compared with EMs. The pharmacoeconomic value of CYP2C19 genotyping remains unclear. Our calculations suggest that genotyping for CYP2C19 could save approximately 5000 US dollars for every 100 Asians tested, but none for Caucasian patients. Nevertheless, genotyping for the common alleles of CYP2C19 before initiating PPIs for the treatment of reflux disease and H. pylori infection is a cost effective tool to determine appropriate duration of treatment and dosage regimens. Altered CYP2C19 activity does not seem to increase the risk for adverse drug reactions/interactions of PPIs. Phenytoin plasma concentrations and toxicity have been shown to increase in patients taking inhibitors of CYP2C19 or who have variant alleles and, because of its narrow therapeutic range, genotyping of CYP2C19 in addition to CYP2C9 may be needed to optimise the dosage of phenytoin. Increased risk of toxicity of tricyclic antidepressants is likely in patients whose CYP2C19 and/or CYP2D6 activities are diminished. CYP2C19 is a major enzyme in proguanil activation to cycloguanil, but there are no clinical data that suggest that PMs of CYP2C19 are at a greater risk for failure of malaria prophylaxis or treatment. Diazepam clearance is clearly diminished in PMs or when inhibitors of CYP2C19 are coprescribed, but the clinical consequences are generally minimal. Finally, many studies have attempted to identify relationships between CYP2C19 genotype and phenotype and susceptibility to xenobiotic-induced disease, but none of these are compelling.
Similar articles
- Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.Bertilsson L.Bertilsson L.Clin Pharmacokinet. 1995 Sep;29(3):192-209. doi: 10.2165/00003088-199529030-00005.Clin Pharmacokinet. 1995.PMID:8521680Review.
- The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.de Leon J, Susce MT, Murray-Carmichael E.de Leon J, et al.Mol Diagn Ther. 2006;10(3):135-51. doi: 10.1007/BF03256453.Mol Diagn Ther. 2006.PMID:16771600Review.
- Pharmacogenomics of proton pump inhibitors.Furuta T, Shirai N, Sugimoto M, Ohashi K, Ishizaki T.Furuta T, et al.Pharmacogenomics. 2004 Mar;5(2):181-202. doi: 10.1517/phgs.5.2.181.27483.Pharmacogenomics. 2004.PMID:15016609Review.
- Applications of CYP450 testing in the clinical setting.Samer CF, Lorenzini KI, Rollason V, Daali Y, Desmeules JA.Samer CF, et al.Mol Diagn Ther. 2013 Jun;17(3):165-84. doi: 10.1007/s40291-013-0028-5.Mol Diagn Ther. 2013.PMID:23588782Free PMC article.Review.
- The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.Ishizawa Y, Yasui-Furukori N, Takahata T, Sasaki M, Tateishi T.Ishizawa Y, et al.Clin Pharmacokinet. 2005;44(11):1179-89. doi: 10.2165/00003088-200544110-00005.Clin Pharmacokinet. 2005.PMID:16231968
Cited by
- Enriching Medication Review with a Pharmacogenetic Profile - A Case of Tamoxifen Adverse Drug Reactions.Jeiziner C, Stäuble CK, Lampert ML, Hersberger KE, Meyer Zu Schwabedissen HE.Jeiziner C, et al.Pharmgenomics Pers Med. 2021 Feb 19;14:279-286. doi: 10.2147/PGPM.S285807. eCollection 2021.Pharmgenomics Pers Med. 2021.PMID:33642872Free PMC article.
- Key mutations alter the cytochrome P450 BM3 conformational landscape and remove inherent substrate bias.Butler CF, Peet C, Mason AE, Voice MW, Leys D, Munro AW.Butler CF, et al.J Biol Chem. 2013 Aug 30;288(35):25387-25399. doi: 10.1074/jbc.M113.479717. Epub 2013 Jul 3.J Biol Chem. 2013.PMID:23828198Free PMC article.
- The Role of Genetic Polymorphism and Other Factors on Clopidogrel Resistance (CR) in an Asian Population with Coronary Heart Disease (CHD).Akkaif MA, Daud NAA, Sha'aban A, Ng ML, Abdul Kader MAS, Noor DAM, Ibrahim B.Akkaif MA, et al.Molecules. 2021 Apr 1;26(7):1987. doi: 10.3390/molecules26071987.Molecules. 2021.PMID:33915807Free PMC article.Review.
- Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.Michaud V, Kreutz Y, Skaar T, Ogburn E, Thong N, Flockhart DA, Desta Z.Michaud V, et al.Pharmacogenomics J. 2014 Apr;14(2):151-9. doi: 10.1038/tpj.2013.17. Epub 2013 Apr 30.Pharmacogenomics J. 2014.PMID:23629159Free PMC article.
- High prevalence of CYP2C19*2 allele in Roma samples: study on Roma and Hungarian population samples with review of the literature.Sipeky C, Weber A, Szabo M, Melegh BI, Janicsek I, Tarlos G, Szabo I, Sumegi K, Melegh B.Sipeky C, et al.Mol Biol Rep. 2013 Aug;40(8):4727-35. doi: 10.1007/s11033-013-2569-4. Epub 2013 May 5.Mol Biol Rep. 2013.PMID:23645039Review.
References
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials